Notch1 Promotes Resistance to Cisplatin by Up-regulating Ecto-5'-nucleotidase (CD73) in Triple-negative Breast Cancer Cells

Overview

Journal Cell Death Discov

Date 2023 Jun 30

PMID 37391408

Authors

Yuzhu Qi

Meifang Li

Shaozhong Li

De Zeng

Yingsheng Xiao

Jiwei Li

Qianqian Ye

Edwin Bremer

Guo-Jun Zhang

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) is an aggressive molecular subtype that due to lack of druggable targets is treated with chemotherapy as standard of care. However, TNBC is prone to chemoresistance and associates with poor survival. The aim of this study was to explore the molecular mechanisms of chemoresistance in TNBC. Firstly, we found that the mRNA expression of Notch1 and CD73 in cisplatin-treated patient material associated with poor clinical outcome. Further, both were upregulated at the protein level in cisplatin-resistant TNBC cell lines. Overexpression of Notch1 intracellular domain (termed N1ICD) increased expression of CD73, whereas knockdown of Notch1 decreased CD73 expression. Using chromatin immunoprecipitation and Dual-Luciferase assay it was identified that N1ICD directly bound the CD73 promoter and activated transcription. Taken together, these findings suggest CD73 as a direct downstream target of Notch1, providing an additional layer to the mechanisms underlying Notch1-mediated cisplatin resistance in TNBC.

Citing Articles

Divide and Conquer-Targeted Therapy for Triple-Negative Breast Cancer.

Nedeljkovic M, Vuletic A, Mirjacic Martinovic K Int J Mol Sci. 2025; 26(4).

PMID: 40003864 PMC: 11855393. DOI: 10.3390/ijms26041396.

Extracting Knowledge from Machine Learning Models to Diagnose Breast Cancer.

Martinez-Ramirez J, Carmona C, Ramirez-Exposito M, Martinez-Martos J Life (Basel). 2025; 15(2).

PMID: 40003620 PMC: 11856414. DOI: 10.3390/life15020211.

Comprehensive pan-cancer analysis of CD73: Explore its association with prognosis and tumor immune microenvironment.

Chen C, Liu S, Ma Y Heliyon. 2024; 10(22):e40329.

PMID: 39624281 PMC: 11609644. DOI: 10.1016/j.heliyon.2024.e40329.

Advances in the Understanding of the Pathogenesis of Triple-Negative Breast Cancer.

Liu Y, Zou Y, Ye Y, Chen Y Cancer Med. 2024; 13(22):e70410.

PMID: 39558881 PMC: 11574469. DOI: 10.1002/cam4.70410.

MiR-338-5p, a novel metastasis-related miRNA, inhibits triple-negative breast cancer progression by targeting the ETS1/NOTCH1 axis.

Chen W, Ye Q, Wu H, Wu Z, Lan Y, Fang Z Heliyon. 2024; 10(15):e34949.

PMID: 39157351 PMC: 11327603. DOI: 10.1016/j.heliyon.2024.e34949.

References

Bai L, Wang A, Zhang Y, Xu X, Zhang X . Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway. Exp Cell Res. 2018; 366(2):161-171. DOI: 10.1016/j.yexcr.2018.03.014. View

Wawruszak A, Luszczki J, Kalafut J, Okla K, Halasa M, Rivero-Muller A . Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis. Int J Mol Sci. 2019; 20(15). PMC: 6696008. DOI: 10.3390/ijms20153663. View

Kordass T, Osen W, Eichmuller S . Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E. Front Immunol. 2018; 9:813. PMC: 5915482. DOI: 10.3389/fimmu.2018.00813. View

Liu M, Siu M, Liu S, Yam J, Ngan H, Chan D . Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. Oncotarget. 2014; 5(4):944-58. PMC: 4011596. DOI: 10.18632/oncotarget.1458. View

Loi S, Pommey S, Haibe-Kains B, Beavis P, Darcy P, Smyth M . CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A. 2013; 110(27):11091-6. PMC: 3704029. DOI: 10.1073/pnas.1222251110. View

Nevedomskaya E, Perryman R, Solanki S, Syed N, Mayboroda O, Keun H . A Systems Oncology Approach Identifies NT5E as a Key Metabolic Regulator in Tumor Cells and Modulator of Platinum Sensitivity. J Proteome Res. 2015; 15(1):280-90. DOI: 10.1021/acs.jproteome.5b00793. View

Samanta D, Park Y, Ni X, Li H, Zahnow C, Gabrielson E . Chemotherapy induces enrichment of CD47/CD73/PDL1 immune evasive triple-negative breast cancer cells. Proc Natl Acad Sci U S A. 2018; 115(6):E1239-E1248. PMC: 5819443. DOI: 10.1073/pnas.1718197115. View

Bray S . Notch signalling in context. Nat Rev Mol Cell Biol. 2016; 17(11):722-735. DOI: 10.1038/nrm.2016.94. View

Baghbani E, Noorolyai S, Rahmani S, Shanehbandi D, Shadbad M, Aghebati-Maleki L . Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study. Biomed Pharmacother. 2021; 145:112370. DOI: 10.1016/j.biopha.2021.112370. View

10.

Cho S, Lu M, He X, Ee P, Bhat U, Schneider E . Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells. Proc Natl Acad Sci U S A. 2011; 108(51):20778-83. PMC: 3251103. DOI: 10.1073/pnas.1019452108. View

11.

Dou X, Liang Y, Lin H, Wei X, Zhang Y, Bai J . Notch3 Maintains Luminal Phenotype and Suppresses Tumorigenesis and Metastasis of Breast Cancer via Trans-Activating Estrogen Receptor-α. Theranostics. 2017; 7(16):4041-4056. PMC: 5667424. DOI: 10.7150/thno.19989. View

12.

Pelicano H, Zhang W, Liu J, Hammoudi N, Dai J, Xu R . Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential. Breast Cancer Res. 2014; 16(5):434. PMC: 4303115. DOI: 10.1186/s13058-014-0434-6. View

13.

Tu E, McGlinchey K, Wang J, Martin P, Ching S, Floch N . Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC. JCI Insight. 2022; 7(3). PMC: 8855814. DOI: 10.1172/jci.insight.142843. View

14.

Dail M, Wong J, Lawrence J, OConnor D, Nakitandwe J, Chen S . Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. Nature. 2014; 513(7519):512-6. PMC: 4213126. DOI: 10.1038/nature13495. View

15.

Patel P, Yu X, Jaskula-Sztul R, Chen H . Hesperetin activates the Notch1 signaling cascade, causes apoptosis, and induces cellular differentiation in anaplastic thyroid cancer. Ann Surg Oncol. 2014; 21 Suppl 4:S497-504. PMC: 4097979. DOI: 10.1245/s10434-013-3459-7. View

16.

Glorieux C, Xia X, You X, Wang Z, Han Y, Yang J . Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer. J Adv Res. 2022; 40:109-124. PMC: 9481954. DOI: 10.1016/j.jare.2021.12.005. View

17.

Allard B, Pommey S, Smyth M, Stagg J . Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res. 2013; 19(20):5626-35. DOI: 10.1158/1078-0432.CCR-13-0545. View

18.

Bianchini G, Balko J, Mayer I, Sanders M, Gianni L . Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016; 13(11):674-690. PMC: 5461122. DOI: 10.1038/nrclinonc.2016.66. View

19.

Tutt A, Tovey H, Chon U Cheang M, Kernaghan S, Kilburn L, Gazinska P . Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018; 24(5):628-637. PMC: 6372067. DOI: 10.1038/s41591-018-0009-7. View

20.

Islam S, Aboussekhra A . Sequential combination of cisplatin with eugenol targets ovarian cancer stem cells through the Notch-Hes1 signalling pathway. J Exp Clin Cancer Res. 2019; 38(1):382. PMC: 6716935. DOI: 10.1186/s13046-019-1360-3. View